Search

Displaying results 3561 - 3570 of 4437 in total
  1. Drug

    NGN-401

    go.drugbank.com/drugs/DB18594
    Investigational

    Developed by Neurogene Inc., it is being investigated for the treatment of Rett syndrome.

  2. Drug

    Pirfenidone

    go.drugbank.com/drugs/DB04951
    ApprovedInvestigational

    Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneum...

  3. Drug

    Human Umbilical Cord Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15726
    Investigational

    Currently many companies are creating their own version of these stem cells, one of which is by Aspire, who are creating a version named ACT-20. … The cells are extracted by either the explant or the enzymatic digestion method, though neither method has been characterized as the ‘standard’ thus far.

  4. Drug

    Triazolam

    go.drugbank.com/drugs/DB00897
    ApprovedInvestigational

    Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.

  5. Drug

    Rubidium Rb-82

    go.drugbank.com/drugs/DB09479
    ApprovedInvestigational

    Rubidium chloride Rb-82 injection is a sterile nonpyrogenic solutions of rubidium Rb 82 chloride. It is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate ...

  6. Drug

    Afimoxifene

    go.drugbank.com/drugs/DB04468
    Investigational

    It is being developed by Ascent Therapeutics.

  7. Drug

    GS030-DP

    go.drugbank.com/drugs/DB17847
    Investigational

    It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8 vector.

  8. Drug

    AC-003

    go.drugbank.com/drugs/DB22691
    Investigational

    [L53458,L53463] By inhibiting RIPK1 kinase activity, AC-003 thereby inhibits RIPK1-mediated cell death and inflammation.

  9. Drug

    Ty800

    go.drugbank.com/drugs/DB04989
    Investigational

    It is being developed by AVANT Immunotherapeutics, Inc.

  10. Drug

    Talniflumate

    go.drugbank.com/drugs/DB09295
    Investigational

    Phase I trials with talniflumate for the treatment of cystic fibrosis and COPD were completed in August 2001, and phase II trials were performed in Ireland for the treatment of cystic fibrosis but this